Skip to content

Contact
Careers

<img width="171" height="60" src="https://www.durect.com/wp-content/uploads/2022/06/Durect_logo.png" class="custom-logo" alt="Durect Logo Color" srcset="https://www.durect.com/wp-content/uploads/2022/06/Durect_logo.png 1x, https://www.durect.com/wp-content/uploads/2022/06/Durect_logo@2x.png 2x" />

About Us
Epigenetic Regulation
Clinical Development
Partnering & Technologies
Investors
Resources

<img width="171" height="60" src="https://www.durect.com/wp-content/uploads/2022/06/Durect_logo.png" class="custom-logo" alt="Durect Logo Color" srcset="https://www.durect.com/wp-content/uploads/2022/06/Durect_logo.png 1x, https://www.durect.com/wp-content/uploads/2022/06/Durect_logo@2x.png 2x" />

AASLD: Durect’s alcoholic hepatitis med repairs liver, cuts mortality in phase 2

Post navigation

← Previous Resource

Next Resource →

Search

About Us
Epigenetic Regulation
Clinical Development
Partnering & Technologies
Investors
Resources
- Publications
- Factsheets
Contact
Careers

About Us
Epigenetic Regulation
Clinical Development
Partnering & Technologies
Investors
Resources
- Publications
- Factsheets
Contact
Careers

Company

About Us
Leadership
Board of Directors
Partnering
Careers
Contact

Science

Epigenetic Regulation
Clinical Development
Pipeline
AH
NASH
Clinical Trials

Resources

Publications
Media Kit
Factsheets

Investors

Overview
Stock Information
FAQs
SEC Filings
Press Releases
Information Request

Copyright © 2022 Durect Corporation

Privacy Policy | Legal Notice | Accessibility

Scroll to Top